Mario Rovirosa – CEO, Ferrer
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Founded in 1959, Ferrer is a Spanish multinational privately-held pharmaceutical company headquartered in Barcelona with a presence in over 90 countries. They operate in the pharmaceutical, health, fine chemicals (API), and food sectors. The company has expertise in the fields of cardiology, central nervous system, dermatology, gastroenterology, metabolism, oncology, musculoskeletal system, paediatrics, pain management, and respiratory.
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Alejandro Mora, Ferrer’s country manager for Central America & Caribbean, discusses the complexity of the region’s healthcare systems, the company’s strategy to compete against local players, and the importance for…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
CPH Pharma was the oldest running pharmaceutical company in Portugal until its acquisition by Grupo Ferrer in 2008. Since then, the company has continued to thrive in the marketplace despite…
Our business model is new in the Chilean market and enables us with great flexibility and allows us to focus on demand generation. For Ferrer this is a great window…
In the second part of a two-part interview, Generika Philippines co-founders, Teodoro Ferrer and Julien Bello, go on to discuss the future of generic medicines in the Philippines, the compnay’s…
In part one of a two-part interview, Generika Philippines co-founders Teodoro Ferrer and Julien Bello discuss what led them to start the company, the changing mentality among the Filipino population…
Robert Fabregat, CEO of Biocat, explains how health start-ups in the BioRegion of Catalonia managed to raise a record EUR 238 million in 2021 and why the Spanish region is…
Alta Life Sciences is one of Catalonia’s top venture capital investor groups in the biotech sector. Montserrat Vendrell, partner and a pivotal figure in the development of the region’s life…
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
The Pasqual Maragall Foundation is a Spanish non-profit research organization dedicated to the research of Alzheimer’s disease. Its director, Arcadi Navarro, takes from his decades-long scientific career in genomics to…
VIVEbiotech is a Spanish CDMO specialised in the production of lentiviral vectors used in gene therapy. Its CEO, Dr Gurutz Linazasoro, tells the story of the company’s creation, comments on…
EATRIS, the European Infrastructure for Translational Medicine, is an EU-funded program that facilitates scientific collaboration amongst public institutions from 14 member states. Its scientific director, Dr Toni Andreu, explains how…
Javier Urzay, deputy director of Farmaindustria, the leading pharma industry association in Spain, discusses the main dynamics shaping the sector, including record levels of R&D investment and clinical trials, their…
Biogen’s managing director for Spain, Sergio Teixeira, reflects on the company’s key role in transforming multiple sclerosis and spinal muscular atrophy as examples of the American biotech giant commitment to…
Bial’s general manager for Spain and global director of its epilepsy franchise, Ana Álvarez, highlights the importance of the country for the organization – representing 25 percent of overall sales…
Soon after reaching its 60th anniversary, in 2015, the largest hospital in Catalonia and a group of sister institutions began working on the creation of a new type of campus.…
Dr Manel Juan is part of the team behind the development of the first European CAR-T-cell therapy to treat multiple myeloma, the second most common type of blood cancer. As…
Ángel Luis Rodríguez de la Cuerda, longtime secretary general of AESEG, the trade association of generic producers in Spain, comments on the key role played by generic medicines during the…
See our Cookie Privacy Policy Here
